CN103339133A - 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉 - Google Patents

烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉 Download PDF

Info

Publication number
CN103339133A
CN103339133A CN2011800646121A CN201180064612A CN103339133A CN 103339133 A CN103339133 A CN 103339133A CN 2011800646121 A CN2011800646121 A CN 2011800646121A CN 201180064612 A CN201180064612 A CN 201180064612A CN 103339133 A CN103339133 A CN 103339133A
Authority
CN
China
Prior art keywords
alkyl
group
heteroaryl
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011800646121A
Other languages
English (en)
Chinese (zh)
Other versions
CN103339133B (zh
Inventor
W·J·斯科特
M·默维斯
U·伯默
U·门宁
刘宁姝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN103339133A publication Critical patent/CN103339133A/zh
Application granted granted Critical
Publication of CN103339133B publication Critical patent/CN103339133B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CN201180064612.1A 2010-11-11 2011-11-08 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉 Expired - Fee Related CN103339133B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41250810P 2010-11-11 2010-11-11
US61/412,508 2010-11-11
PCT/EP2011/069634 WO2012062745A1 (en) 2010-11-11 2011-11-08 Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Publications (2)

Publication Number Publication Date
CN103339133A true CN103339133A (zh) 2013-10-02
CN103339133B CN103339133B (zh) 2016-06-15

Family

ID=44999755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180064612.1A Expired - Fee Related CN103339133B (zh) 2010-11-11 2011-11-08 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉

Country Status (7)

Country Link
US (1) US9730943B2 (und)
EP (1) EP2638044B1 (und)
JP (1) JP6165058B2 (und)
CN (1) CN103339133B (und)
CA (1) CA2817312A1 (und)
ES (1) ES2646012T3 (und)
WO (1) WO2012062745A1 (und)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965203A (zh) * 2014-05-29 2014-08-06 枣庄学院 一类咪唑[1,2-c]-喹唑啉-3（2H）-酮稠杂环化合物及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062743A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
US10117874B2 (en) 2013-12-03 2018-11-06 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
WO2015082378A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
WO2021260443A1 (en) * 2020-06-24 2021-12-30 Bayer Aktiengesellschaft Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
WO2007080419A1 (en) * 2006-01-13 2007-07-19 Crysoptix K.K. Organic compound, anisotropic optical film and method of production thereof
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
WO2010034414A1 (en) * 2008-09-24 2010-04-01 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
KR101154101B1 (ko) * 2003-10-03 2012-06-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 알콕시 치환된 이미다조퀴놀린
WO2005080392A1 (ja) * 2004-02-19 2005-09-01 Takeda Pharmaceutical Company Limited ピラゾロキノロン誘導体およびその用途
WO2012062743A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
WO2007080419A1 (en) * 2006-01-13 2007-07-19 Crysoptix K.K. Organic compound, anisotropic optical film and method of production thereof
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
WO2010034414A1 (en) * 2008-09-24 2010-04-01 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965203A (zh) * 2014-05-29 2014-08-06 枣庄学院 一类咪唑[1,2-c]-喹唑啉-3（2H）-酮稠杂环化合物及其制备方法

Also Published As

Publication number Publication date
EP2638044A1 (en) 2013-09-18
ES2646012T3 (es) 2017-12-11
US9730943B2 (en) 2017-08-15
US20130330327A1 (en) 2013-12-12
WO2012062745A1 (en) 2012-05-18
JP2013542237A (ja) 2013-11-21
CN103339133B (zh) 2016-06-15
CA2817312A1 (en) 2012-05-18
EP2638044B1 (en) 2017-08-30
JP6165058B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
CN102906094B (zh) 用于治疗过度增殖性病症和与血管发生相关的疾病的氨基醇取代的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物
CN103370320B (zh) 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
JP5326092B2 (ja) 高増殖性疾患及び血管形成関連疾患の治療に有用な置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体
CN105263497B (zh) 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
JP5620275B2 (ja) 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
CN103339133B (zh) 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103608018A (zh) 取代的2,3-二氢咪唑并[1,2-c]喹唑啉的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189594

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1189594

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160615

Termination date: 20181108

CF01 Termination of patent right due to non-payment of annual fee